Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G. Singal, Eli Pikarsky, Sasan Roayaie, Riccardo Lencioni, Kazuhiko Koike, Jessica Zucman‐Rossi, Richard S. Finn (2021). Hepatocellular carcinoma. Nature Reviews Disease Primers, 7(1), DOI: 10.1038/s41572-020-00240-3.
Article347 days agoMolecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, Anthony B. El-Khoueiry, Helen L. Reeves, Xin Wei Wang, Gregory J. Gores, Augusto Villanueva (2022). Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 3(4), pp. 386-401, DOI: 10.1038/s43018-022-00357-2.
Article347 days agoAuthor Correction: Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G. Singal, Eli Pikarsky, Sasan Roayaie, Riccardo Lencioni, Kazuhiko Koike, Jessica Zucman‐Rossi, Richard S. Finn (2024). Author Correction: Hepatocellular carcinoma. Nature Reviews Disease Primers, 10(1), DOI: 10.1038/s41572-024-00500-6.
Article347 days agoCabozantinib: An evolving therapy for hepatocellular carcinoma
Anthony B. El-Khoueiry, Diana L. Hanna, Josep M. Llovet, Robin Kate Kelley (2021). Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 98, pp. 102221-102221, DOI: 10.1016/j.ctrv.2021.102221.
Article347 days agoSO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Bruno Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, Enrico de Toni, Junji Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Thông Dao, Satheesh Chiradoni Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Charu Gupta, Alejandra Negro, Ghassan K. Abou‐Alfa (2023). SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. , 34, DOI: https://doi.org/10.1016/j.annonc.2023.04.487.
Article9 days ago